“Johnson & Johnson vaccine makes up less than 5 percent of the recorded shots in arms in the United States to date,” White House Covid-19 coordinator Jeff Zients mentioned in a assertion. “Based on actions taken by the President earlier this year, the United States has secured enough Pfizer and Moderna doses for 300 million Americans. Over the last few weeks, we have made available more than 25 million doses of Pfizer and Moderna each week, and in fact this week we will make available 28 million doses of these vaccines.”

The early morning announcement from the Food and Drug Administration and the US Centers for Disease Control and Prevention that they had been pausing use of the J&J vaccine triggered a scramble in states that had been getting ready to manage it. All federal well being channels — mass vaccination websites, neighborhood well being facilities and different services — that had been beforehand administering the Johnson & Johnson vaccine will instantly cease in the interim, in response to a federal well being official.

The companies are recommending that states do the identical, although the person well being officers in these areas will make the final word choice as a result of they’re given a separate allocation of doses.

The FDA and CDC mentioned that six ladies who obtained the shot, out of 6.8 million doses administered, skilled a uncommon and extreme sort of blood clot. The pause occurred as a result of the sort of blood clot is not listed on the record of potential antagonistic unwanted effects that had been a part of the emergency use authorization for Johnson & Johnson. While officers are stressing it’s uncommon, they need well being care suppliers to have time to know what potential unwanted effects are and greatest deal with them.

In his assertion, Zients mentioned the White House was “working now with our state and federal partners to get anyone scheduled for a J&J vaccine quickly rescheduled for a Pfizer or Moderna vaccine.”

White House financial adviser Jared Bernstein mentioned Tuesday the administration is taking it “extremely seriously” and largely declined to forecast what the pause means for reopening the economic system.

“I’ve already heard that the White House medical team is poring over these data, looking into it, taking this extremely seriously. But it would be unwise for me to lean any further into that until we hear from them,” he mentioned throughout an look on CNBC.

Concerns over hesitancy

White House officers are privately voicing concern Tuesday morning that the pause of the Johnson & Johnson vaccine will contribute to vaccine hesitancy, which they had been getting ready to fight now that provide is ramping up.

Officials on the White House had been knowledgeable late Monday evening of the choice to pause the Johnson & Johnson rollout and conduct a evaluate, a particular person aware of the state of affairs says. White House officers have been on the telephones with governors all morning, and the weekly governors name on the pandemic is scheduled to happen shortly.

For months, federal well being officers have expressed issues on the massive variety of Americans who appear hesitant to receive a shot. Concerns about well being problems, even when extremely unlikely, might immediate extra Americans to refuse vaccines. The same danger related to a vaccine produced by AstraZeneca, which is not approved to be used within the United States, has brought about hesitancy issues in Europe.
A serious public messaging marketing campaign designed to fight hesitancy in key demographic teams — together with folks of colour, conservatives and younger Americans — launched late last month. But officers have nonetheless voiced concern that enormous swaths of the nation could decline to be vaccinated.

While federal officers are stressing the blot clot problem in query is exceedingly uncommon, they need well being care suppliers to have time to know what the potential unwanted effects of the vaccine are and greatest deal with them.

The CDC and FDA got here to a choice late final evening to pause use of the vaccine, a federal well being official mentioned. The two companies performed a press name Tuesday to reply extra questions in regards to the improvement.

“This whole thing developed late last night, and it was decided that Dr. (Anne) Schuchat would talk to the media and Dr. (Rochelle) Walensky would talk to the governors this morning. They’re trying to communicate this as quickly as possible, and so there was a division of labor,” one federal official mentioned, referring to the highest two officers within the CDC.

Health and Human Services Secretary Xavier Becerra was made conscious of the CDC and FDA’s choice to briefly pause using Johnson & Johnson’s Covid-19 vaccine Monday evening, a HHS official mentioned.

“We will wait for the FDA to review, make a decision and we’ll go from there,” the official mentioned.

According to 1 state official, their state did not obtain a heads up the federal authorities can be recommending pausing the vaccine. This official, who spoke on the situation of anonymity given the sensitivity of the subject, mentioned they had been in conversations looking for extra data from the federal authorities on the event, which the official mentioned would damage their efforts to fight vaccine hesitancy.

CDC and FDA recommend US pause use of Johnson & Johnson's Covid-19 vaccine over blood clot concernsCDC and FDA recommend US pause use of Johnson & Johnson's Covid-19 vaccine over blood clot concerns

“You have no idea how this is going to impact vaccine hesitancy,” the official mentioned. “Following this you cannot blame any states for hesitancy issues.”

A separate official from a northeast state mentioned they had been additionally given no heads up, and had been shocked once they discovered the information.

“If you want to ramp up vaccine hesitancy — this is exactly how you do it,” the official bemoaned, including that governors shall be on a name with Zients Tuesday morning and that states want solutions.

This official, who additionally spoke on the situation of anonymity, mentioned their state had simply loaded all of their cellular models with Johnson & Johnson’s vaccine and had been scrambling to determine deal with the state of affairs.

Moderna and Pfizer pictures must be sufficient to satisfy Biden’s objectives

Biden has mentioned that each one grownup Americans shall be eligible to obtain a vaccine by April 19 — subsequent Monday — and has set a purpose of vaccinating 200 million Americans by the top of April. The administration has mentioned there shall be enough provide to vaccinate 300 million Americans by the top of July, however has acknowledged that it might take longer to really administer the pictures.

The US has bought a mixed 600 million doses of the Pfizer and Moderna vaccines, sufficient to vaccinate 300 million folks. But the administration had additionally been relying on Johnson & Johnson’s product, which requires solely a single shot and will be saved at a decrease temperature than the opposite two accepted merchandise, to vaccinate harder-to-reach populations.

On Monday, earlier than the pause was determined upon and introduced, White House officers informed reporters that the US would nonetheless be on monitor to achieve its Covid-19 vaccination targets even with out further doses from Johnson & Johnson’s vaccine. Andy Slavitt, the White House’s senior adviser for Covid-19 response, mentioned that there had been 90 million doses of Covid-19 vaccine delivered within the final three weeks “and you can expect even without additional doses from Johnson & Johnson for us to be somewhere in that neighborhood.”

“If you do the math, there is plenty of supply to continue to vaccinate Americans at 3 million per day, and then some. That’s not to mention the fact that there are many doses that have already been distributed into states,” Slavitt mentioned. “I think we’re in the fortunate position, we have to remind ourselves, where we have three vaccines approved that are very effective vaccines, but we are also importantly not dependent upon this.”

This story has been up to date with further data.